linjc16/ctgov huggingface dataset:
Blood Pressure Measuring Practice of Hong Kong Primary Care Doctors

Study Overview
=================
Brief Summary
-----------------
Background: While office BP measurements were traditionally used to detect, diagnose and manage hypertension(HT), studies had convincingly showed that out-of-office blood pressure, including home blood pressure monitoring (HBPM) and ambulatory blood pressure monitoring (ABPM), was superior in predicting cardiovascular outcomes and death. Furthermore, some countries' guidelines suggested the use of validated automatic blood pressure machines (called automated office blood pressure monitoring (AOBP)) to screen for HT and record BP in routine HT clinical management. With difference between guidelines and various available BP measurement methods, it is not known how primary care doctors, who play the key role to detect and treat HT, are measuring BP in their daily practice. Method: All doctors registered in the primary care directory will be mailed a questionnaire. Those who do not respond would be mailing for maximally 3 times, 2 weeks apart to enhance response rate. It is estimated that around 1500-2000 doctors will be eligible.

Official Title
-----------------
Blood Pressure Measuring Practice of Hong Kong Primary Care Doctors: a Cross-sectional Study

Conditions
-----------------
Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All doctors registered in the primary care directory in Hong Kong Exclusion Criteria: nil

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the blood pressure (BP) measurement method for screening of hypertension | possible answers included: Manual BP in the office with mercury or aneroid device; Manual BP in the office with an electronic device; Automated office BP machines (AOBP) ; Other patient-activated electronic devices in the office; Electronic BP kiosks | 1 year | 
| The BP measurement method to diagnose hypertension | possible answers included: Manual BP in the office with mercury or aneroid device; Manual BP in the office with an electronic device; Automated office BP machines (AOBP) ; Other patient-activated electronic devices in the office; Electronic BP kiosks; Ambulatory BP monitoring (24-hour to 48-hour BP monitoring); home BP monitoring | 1 year | 
| your routine methods used to measure BP in patients taking antihypertensive treatment (lifestyle or medications) | possible answers included: Manual BP in the office with mercury or aneroid device; Manual BP in the office with an electronic device; Automated office BP machines (AOBP) ; Other patient-activated electronic devices in the office; Electronic BP kiosks; Ambulatory BP monitoring (24-hour to 48-hour BP monitoring); home BP monitoring | 1 year |
Safety of Autologous M2 Macrophage in Treatment of Non-Acute Stroke Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether M2 macrophages are safe and feasible in the treatment of non-acute stroke patients

Detailed Description
-----------------
Our primary hypothesis is that autologous M2 macrophage transplantation via intrathecal introduction is feasible and safe after non-acute stroke. Our secondary hypothesis is that autologous M2 macrophage transplantation is associated with improved neurological outcome after non-acute stroke

Official Title
-----------------
Safety and Feasibility of Autologous M2 Macrophage Transplantation in Treatment of Non-Acute Stroke Patients

Conditions
-----------------
Ischemic Stroke, Hemorrhagic Stroke

Intervention / Treatment
-----------------
* Other: M2 macrophage introduction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Computed tomography confirmed ischemic or hemorrhagic stroke Duration since stroke onset more than 3 and less than 12 months Age between 18 and 75 years old Persistent neurological deficits more than 4 points in NIHSS stroke scale Signed informed consent Exclusion Criteria: The history of previous stroke Seizures Thrombophilias or primary hematological diseases Malignancy Hepatic or renal dysfunctions Hemodynamic or respiratory instability Autoimmune disease HIV or uncontrolled bacterial, fungal, or viral infections Pregnancy Participation in other clinical trials

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: M2 macrophages<br>M2 macrophage introduction | Other: M2 macrophage introduction<br>* Generation of autologous M2 macrophages from peripheral blood of non-acute stroke patients Intrathecal introduction of autologous M2 macrophages<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of patients with severe adverse events | Occurence of severe adverse events including mortality, neurological worsening and seizures | 1-3 days, 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement of functional outcome in National Institutes of Health Stroke Scale (NIHSS) |  | 1-3 days, 6 months | 
| Improvement in Barthel Index |  | 1-3 days, 6 months | 
| Improvement in modified Rankin scale |  | 1-3 days, 6 months |
Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
The Purpose of This Study is to Evaluate the Efficacy and Safety of Acarbose in Type 2 Diabetic Patients Using Two Different Formulations of Acarbose 50mg.

Detailed Description
-----------------
Study Design: Multicenter Phase III Randomized Double Blind Prospective and Comparative Experiment duration: 105 days 5 visits Efficacy Adverse event

Official Title
-----------------
A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: EMS Acarbose
* Drug: Bayer Acarbose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must be able to understand the study procedures agree to participate and give written consent. Diagnosed with type 2 diabetes mellitus (t2dm)b Female patients of childbearing potential (i.e., ovulating, pre-menopausal, not surgically sterile) which agree to use a medically accepted contraceptive regimen for the duration of the study. Exclusion Criteria: Pregnancy or risk of pregnancy. Lactation Any pathology or past medical condition that can interfere with this protocol Other conditions deemed reasonable by the medical investigator as to the disqualification of the individual from study participation. Known hypersensitivity / intolerance to acarbose or any of its excipients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EMS Acarbose<br> | Drug: EMS Acarbose<br>* EMS Acarbose 50 mg 3 times a day<br>|
| Active Comparator: Bayer Acarbose<br> | Drug: Bayer Acarbose<br>* Bayer Acarbose 50 mg 3 times a day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glycosylated hemoglobin (HbA1c) |  | Change from baseline to day 98 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decrease in mean Fasting Plasma Glucose (FPG) |  | Change from baseline to day 14, 28, 42, 70 and 98 | 
| Safety will be evaluated by the Adverse events occurence | Adverse events will be collected and followed in order to evaluate safety and tolerability | Day 105 |
Effect of Intraoperative IV Ketamine on Postoperative Morphine Consumption During Intestinal Surgery

Study Overview
=================
Brief Summary
-----------------
.The aim of this study is to identify the analgesic effect of intraoperative ketamine intravenous infusion on patients undergoing intestinal surgery and its effect on salivary cortisol and alpha amylase levels as indicator of its effect.

Detailed Description
-----------------
I- Group K (ketamine): 30 patients will receive intraoperative intravenous ketamine infusion. II- Group C (control): 30 patients will receive intraoperative intravenous normal saline infusion.

Official Title
-----------------
Effect of Intraoperative IV Ketamine on Postoperative Morphine Consumption During Intestinal Surgery and Its Effect on Salivary Cortisol and Alpha Amylase Levels

Conditions
-----------------
Postoperative Analgesia

Intervention / Treatment
-----------------
* Drug: Ketamine Hydrochloride
* Drug: Normal saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patient's status ASA status-I and II. Patients age above 18 years old. Patients scheduled for intestinal surgery. Exclusion Criteria: Patient refusal. Patients with known allergy to ketamine or morphine. Patients with significant hepatic dysfunction. Patients with severe renal disease. Significant Heart disease. Patients with chronic pain. Regular use analgesics, antidepressants or opioids in last 2 months. Any known convulsive disorder. Morbid obesity (BMI>35). Patients with autoimmune disease Patients on corticosteroid therapy Pregnancy. Breast feeding. Woman under hormonal treatment. Oral disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: ketamine hydrochloride<br>intravenous ketamine infusion in the intraoperative period | Drug: Ketamine Hydrochloride<br>* intravenous ketamine infusion intraoperatively<br>* Other names: ketalar;|
| Active Comparator: normal saline<br>intravenous normal saline infusion in the intraoperative period | Drug: Normal saline<br>* intravenous normal saline infusion intraoperatively<br>* Other names: Sodium chloride solution;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| morphine consumption | IV PCA | 2 days postoperative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cortisol level | salivary | 2 days postoperative | 
| alpha amylase level | salivary | 2 days postoperative |
Effect of Body Composition and Metabolism on Oocyte Gene Expression

Study Overview
=================
Brief Summary
-----------------
The investigators will test the hypothesis that obese women have a unique oocyte gene expression profile that differs significantly from that of normal weight women.

Official Title
-----------------
Effect of Body Composition and Metabolism on Oocyte Gene Expression

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI < 25 (N=35) or BMI ≥ 30 (N=35) Seeking fertility treatment at the Arkansas Fertility and Gynecology Associates Clinic Assisted reproduction will include the oocyte retrieval technique 18 to 38 years of age Exclusion Criteria: Any health condition or medication that may interfere with the study outcome as determined by the investigators

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 38 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| oocyte gene expression profile |  | 1-2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
healthy women, oocytes, in vitro fertilization, pregnancy, childbearing-age
SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

Study Overview
=================
Brief Summary
-----------------
SHARE: Simple HAART with Abacavir, Reyataz, and Epivir

Detailed Description
-----------------
Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24 weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA <50 copies/mL at entry

Official Title
-----------------
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks

Conditions
-----------------
HIV Infections, Lipodystrophy

Intervention / Treatment
-----------------
* Drug: atazanavir (Reyataz)
* Drug: ritonavir (Norvir)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen Viral load <50 copies/ml Exclusion Criteria: Viral load >50 copies/ml Having taken more than one antiretroviral regimen

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: atazanavir (Reyataz)|nan|
|Drug: ritonavir (Norvir)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, Reyataz, atazanavir, Norvir, ritonavir, Boosted, Lipodystrophy, Treatment Experienced
Survey on Cardiovascular Events in Patients With Metabolic Disease on Chronic Carnitine Supplementation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to learn about the effects of long term carnitine use in patients with metabolic disorders and its potential relationship to cardiovascular events.

Detailed Description
-----------------
This online cross-sectional survey will examine the self-reported long-term carnitine use in patients with metabolic disorders and any potential relationship to cardiovascular events.

Official Title
-----------------
Survey on Cardiovascular Events in Patients With Metabolic Disease on Chronic Carnitine Supplementation

Conditions
-----------------
Metabolic Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of mitochondrial disease or any other metabolic disorder Any age group NAMDC or RDCRN registry participant Exclusion Criteria: Inability to provide informed consent and complete survey Lack of participation in NAMDC or RDCRN registry
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess how many patients with metabolic disorders are on chronic carnitine supplementation. |  | Up to one year from study activation. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess how many patients who are on chronic carnitine supplementation have experienced a cardiovascular event. |  | Up to one year from study activation |
Study Evaluating TTI-237 in Advanced Malignant Solid Tumors

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.

Official Title
-----------------
A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously Every 3 Weeks in Subjects With Advanced Malignant Solid Tumors

Conditions
-----------------
Neoplasms

Intervention / Treatment
-----------------
* Drug: TTI-237


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Documented diagnosis of malignant solid tumor with measurable disease Life expectancy of at least 12 weeks ECOG performance status of 0, 1, or 2 Exclusion Criteria: Recent major surgery, radiation therapy or anti-cancer treatment History of any other prior malignancy within the last 5 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: TTI-237|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary purpose is to address the safety and tolerability of TTI-237. Patient will be assessed on an ongoing basis during their participation on the trial. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Preliminary pharmacokinetics (cycle 1 only) and anti-tumor activity of TTI-237 (approximately every 8 weeks). |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tumors, Advanced malignant solid tumors
Evaluation of the Dental Movements Caused by Oral Appliance in Sleep Apnea Syndrome

Study Overview
=================
Brief Summary
-----------------
The DO OAM study is a mono-center, interventional, prospective study carried out in CH VALENCE. It will estimate the prevalence of dental movements in patients treated by oral Appliance for Sleep Apnea syndrome. The investigators will used fingerprinting technique by taking multiple photographs of the teeth that allow for the three-dimensional reconstruction of the teeth this study will provide a better understanding of dental movement caused by oral appliance

Detailed Description
-----------------
oral appliances are indicated for the treatment of Sleep Apnea syndrome. Dentoskeletal effects of oral Appliance are imperfectly assessed. the investigators want to study dental movements by comparing three-dimensional reconstruction of the teeth and the dental articulation in patients treated for sleep apnea syndrome in our Hospital. The study consists of an additional acquisition of three-dimensional reconstruction of teeth. the data previously acquired during the first digital impression according usual practise will be compared to this additional acquisition.

Official Title
-----------------
Evaluation of the Dental Movements Caused by Oral Appliance in Syndrome Sleep Apnea Syndrome(DPOAM)

Conditions
-----------------
Sleep Apnea Syndromes

Intervention / Treatment
-----------------
* Other: prevention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with a diagnosis of sleep apnea syndrome treated by Oral appliances in CH Valence Availability of previous digital impressions required for Oral appliances manufacturing Age ≥ 18 years old Read, write and understand the French language Exclusion Criteria: Patient under guardianship, deprived of liberty, safeguard of justice Refusal to participate in research

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Interventional Model Description: cohort
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: open label<br>Single Group Assignment | Other: prevention<br>* dental digital fingerprinting<br>* Other names: dental digital fingerprinting;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| dental movement | dental length rotation (mm) | 1 DAY at inclusion visit only | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
oral appliance, dental movement